New AML combo trial halted early after enrolling 15 patients
NCT ID NCT03055286
First seen Jan 07, 2026 · Last updated May 12, 2026 · Updated 13 times
Summary
This study tested a new drug called CWP232291 combined with standard chemotherapy (cytarabine) in people whose acute myeloid leukemia (AML) had returned or stopped responding to treatment. The goal was to find a safe dose and see if the combination could shrink or eliminate the cancer. The trial was terminated early, and only 15 people took part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, Songpa-Gu, South Korea
-
Samsung medical center
Seoul, Gangnam-gu, South Korea
-
Seoul National University Hospital
Seoul, Jongno-gu, South Korea
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Washington
Seattle, Washington, 98195, United States
Conditions
Explore the condition pages connected to this study.